Treatment of acute respiratory viral infection in children aged 12 to 18 years: results of a randomized clinical trial of Raphamin

Authors:

Abstract
Objective. To evaluate the efficacy and safety of Raphamin® in the treatment of acute respiratory viral infections (ARVI) in children. Patients and methods. A multicenter, double-blind, placebo-controlled, randomized study was conducted in an outpatient setting. Of the 435 children 12-18 years old with acute respiratory infections examined, 420 patients who met the eligibility criteria were included (n = 420), randomized 1:1 into group 1 (Raphamin®, n = 206) and group 2 (placebo, n = 214). Treatment was 5 days and follow-up was up to 14 days. Time to resolution of symptoms of acute respiratory infection (confirmed by polymerase chain reaction (PCR)) was assessed, as well as disease severity, proportion of recovered patients, worsening/complications, antipyretic medication use, and safety of therapy. Results. Patients in both groups did not differ in age and sex (mean age 14.3 ± 1.7 years and 14.2 ± 1.7 years in groups 1 and 2, respectively, p = 0.869). Time to resolution of acute respiratory infection (PCR-confirmed) symptoms in group 1 was 3.3 ± 1.7 days vs. 4.4 ± 2.6 days in group 2, p < 0.001. The proportion of patients with resolution of ARVI symptoms on days 2 and 3 of treatment in group 1 reached 13.1 and 29.5% versus 3.7%, p = 0.017, and 15.0%, p = 0.011, of patients in group 2, respectively. The studied drug was well tolerated, no cases of adverse events related to the drug administration were registered. Conclusion. The use of Raphamin® for 5 days in children 12–18 years old with acute respiratory viral infections reduced the time to resolution of all symptoms of the disease by 24 hours, led to an increase in the proportion of recovered patients on the 2–3rd day of therapy and was accompanied by a good safety profile. Key words: children, treatment, acute respiratory viral infection, antiviral therapy, Raphamin®